Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I study of therapy with the farnesyl transferase inhibitor R115777 (Zarnestra) combined with conventional induction and consolidation chemotherapy for previously untreated patients over age 55 with acute myeloid leukemia (AML).

Next Previous
X
Search
Trial Profile

A phase I study of therapy with the farnesyl transferase inhibitor R115777 (Zarnestra) combined with conventional induction and consolidation chemotherapy for previously untreated patients over age 55 with acute myeloid leukemia (AML).

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 29 Jul 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tipifarnib (Primary) ; Cytarabine; Daunorubicin
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Pharmacokinetics

    • Most Recent Events

    • 16 Mar 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
    • 16 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Dec 2007 The expected completion date for this trial is now 1 Jun 2008.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top